Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 2Rectal Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Melanoma 1Hemangiosarcoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 11Leucovorin 10Oxaliplatin 9Bevacizumab 6Irinotecan 5Capecitabine 3regorafenib 2aflibercept 2Folfox protocol 2Exercise 2Chemotherapy, Adjuvant 2Cetuximab 2Biopsy 2Atorvastatin 2tucatinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1sulindac sulfone 1sargramostim 1retrovector encoding mutant anti-cyclin G1 1poly ICLC 1pidilizumab 1pembrolizumab 1p53 peptide 264-272, human 1nilotinib 1monalizumab 1lonafarnib 1irofulven 1infigratinib 1grp protein, Drosophila 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Colonic Neoplasms × balstilimab × Clear all
NCT06575725 2024-11-21

Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

City of Hope Medical Center

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡